ANTXR1 and triple-negative breast carcinoma: Likewise, CAR T cell-based immunotherapy targeting ANTXR1/TEM8 has been developed and shown to have cytotoxic specificity for tumor endothelial cells as well as ANTXR1-positive triple-negative breast cancer cells [46] or gastric adenocarcinoma cells [47].